Sophie Catteau-Jonard
No ORCID on file
· 6 papers in corpus
other
2026
BACKGROUND: Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), is characterised by neuroendocrine dysfunction with accelerated gonadotrophin-releasing hormone (GnRH)/luteinising hormone (LH) …
rct
2025
PURPOSE: We aimed to assess the impact of the timing of ovarian stimulation initiation on the number of oocytes retrieved in a progestin-primed ovarian stimulation (PPOS) protocol for oocyte donors. METHODS: A total of 110 oocyte donors wer…
observational
2025
INTRODUCTION: Cardiovascular disease remains the leading cause of death among women. Across the lifespan, exposure to both traditional and lifestyle-related cardiovascular risk factors (CVRFs) is high. Behavioral trends such as increased se…
observational
2024
RESEARCH QUESTION: To determine whether the use of oral dydrogesterone (DYD) in luteal phase support (LPS) during an artificial cycle provides equivalent clinical and ongoing pregnancy, delivery and miscarriage rates as micronized vaginal p…
observational
2023
RESEARCH QUESTION: Clomiphene citrate (CC) is one of the first-line treatments for ovulation induction in women with anovulatory polycystic ovary syndrome (PCOS). However, nearly 1 out of 2 women is resistant to 50 mg/day of CC. The objecti…
observational
2016
BACKGROUND: Pulsatile GnRH therapy is the gold standard treatment for ovulation induction in women having functional hypothalamic amenorrhea (FHA). The use of pulsatile GnRH therapy in FHA patients with polycystic ovarian morphology (PCOM),…